Build Only the Evidence the Next Capital Provider Needs
Learn how TSCIP can connect BD intelligence directly to development and financing decisions.
Home > TSCIP
For Asset Holders
Turn partner interest into an actionable development strategy.
Built for Clinical-Stage Biotech
TSCIP is designed particularly for clinical-stage biotechnology companies facing the difficult moment between scientific validation and a completed transaction.
Common Situations
- Pharma likes the asset, but wants additional data.
- We have limited runway and cannot fund every possible study.
- Repeated Diligence, Same Roadblock
- Strong Combination Potential, No Self-Funding
- Investment Must Increase Transaction Probability
- Counterparty re-engagement
How TSCIP Connects Intelligence to Decisions
TSCIP connects BD intelligence directly to development and financing decisions by aligning every activity around a single question: what must become true for the next party to commit capital?
Assess
Evaluate the asset, competitive environment, development path and potential counterparties.
Validate
Test the proposition with selected pharmaceutical and biotechnology counterparties.
Plan
Convert market feedback into the smallest credible evidence package capable of changing the next decision.
Finance
Identify whether that evidence should be financed internally, strategically or through external development capital.
Transact
Continue engagement through collaboration, option, licensing or other transaction pathways.